Comparator supply for NCT06124157
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Sponsor: National Cancer Institute (NCI) (NIH). Phase: PHASE2. Status: Recruiting. Countries: United States, Australia, Canada, Puerto Rico. Last update posted 2026-09-04.
Registry record: https://clinicaltrials.gov/study/NCT06124157.
Canadian-labelled calaspargase pegol
1 marketed Canadian product(s) from 1 manufacturer(s) contain calaspargase pegol. Available strengths: 3750 UNIT / 5 ML. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled cyclophosphamide
10 marketed Canadian product(s) from 3 manufacturer(s) contain cyclophosphamide. Available strengths: 1000 MG, 200 MG, 2000 MG, 25 MG, 50 MG, 500 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled cyclophosphamide monohydrate
10 marketed Canadian product(s) from 3 manufacturer(s) contain cyclophosphamide. Available strengths: 1000 MG, 200 MG, 2000 MG, 25 MG, 50 MG, 500 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled cytarabine
3 marketed Canadian product(s) from 3 manufacturer(s) contain cytarabine. Available strengths: 100 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled dasatinib
11 marketed Canadian product(s) from 2 manufacturer(s) contain dasatinib. Available strengths: 100 MG, 140 MG, 20 MG, 50 MG, 70 MG, 80 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled dasatinib hydrate
11 marketed Canadian product(s) from 2 manufacturer(s) contain dasatinib. Available strengths: 100 MG, 140 MG, 20 MG, 50 MG, 70 MG, 80 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled dasatinib monohydrate
11 marketed Canadian product(s) from 2 manufacturer(s) contain dasatinib. Available strengths: 100 MG, 140 MG, 20 MG, 50 MG, 70 MG, 80 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled daunorubicin
2 marketed Canadian product(s) from 2 manufacturer(s) contain daunorubicin (daunorubicin hydrochloride). Available strengths: 20 MG, 20 MG / 4 ML. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled doxorubicin
7 marketed Canadian product(s) from 5 manufacturer(s) contain doxorubicin hydrochloride. Available strengths: 150 MG, 2 MG, 50 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled imatinib
16 marketed Canadian product(s) from 8 manufacturer(s) contain imatinib (imatinib mesylate). Available strengths: 100 MG, 400 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled leucovorin
8 marketed Canadian product(s) from 6 manufacturer(s) contain leucovorin (leucovorin calcium). Available strengths: 10 MG, 1000 MG / 100 ML, 5 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled mercaptopurine
2 marketed Canadian product(s) from 2 manufacturer(s) contain mercaptopurine. Available strengths: 50 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled methotrexate
2 marketed Canadian product(s) from 2 manufacturer(s) contain methotrexate. Available strengths: 10 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled methotrexate lpf
2 marketed Canadian product(s) from 2 manufacturer(s) contain methotrexate. Available strengths: 10 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled methotrexate methylaminopterin
2 marketed Canadian product(s) from 2 manufacturer(s) contain methotrexate. Available strengths: 10 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled pegaspargase
1 marketed Canadian product(s) from 1 manufacturer(s) contain pegaspargase. Available strengths: 750 UNIT. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled prednisolone
3 marketed Canadian product(s) from 3 manufacturer(s) contain prednisolone acetate. Available strengths: 1 %. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled prednisone
5 marketed Canadian product(s) from 3 manufacturer(s) contain prednisone. Available strengths: 1 MG, 5 MG, 50 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled prednisone intensol
5 marketed Canadian product(s) from 3 manufacturer(s) contain prednisone. Available strengths: 1 MG, 5 MG, 50 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled thioguanine
1 marketed Canadian product(s) from 1 manufacturer(s) contain thioguanine. Available strengths: 40 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled thioguanine hemihydrate
1 marketed Canadian product(s) from 1 manufacturer(s) contain thioguanine. Available strengths: 40 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled thioguanine hydrate
1 marketed Canadian product(s) from 1 manufacturer(s) contain thioguanine. Available strengths: 40 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled vincristine
2 marketed Canadian product(s) from 2 manufacturer(s) contain vincristine sulfate. Available strengths: 1 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
What we supply
- Canadian-labelled comparator sourced through licensed Canadian supply
- Certificate of Analysis for every batch
- Batch number and expiry documentation, with retained records
- Blinding-ready packaging and over-encapsulation on request
- 2–8 °C validated cold chain with temperature logging where required
- Health Canada Drug Establishment Licence #3-002896
Frequently asked questions
Can Nexara supply Canadian-labelled calaspargase pegol as a trial comparator?
Yes. We source Canadian-marketed calaspargase pegol under Health Canada Drug Establishment Licence #3-002896 and ship it with Certificate of Analysis, batch number and expiry documentation for use as a comparator or rescue supply in NCT06124157.
What documentation comes with each shipment?
Certificate of Analysis, manufacturer batch and expiry records, chain-of-custody documentation from the Canadian supply chain, and temperature records where cold chain applies. Blinding-ready packaging is available on request.
How long does comparator supply take?
Quotes are returned within one business day. Lead time depends on the presentation and the destination country's import route — typically 10 to 21 days once the importer's licence and any notification are in place.
Request comparator quote
Request comparator quote or call +1-431-588-9055.